Life Science Nation Newsletter  |  May 21, 2015  |  Issue 112

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (May. 14 - May. 20)

Seeking Strategic Investments

Looking to In-License Therapeutic Assets

Globally for Therapeutics, Devices and Diagnostic with In-human Data
Seeking Early Stage Therapeutic Investment Opportunities
In This Issue

Getting the Most from a 30-Minute Investor Meeting


Global R&D Is Advancing the Cancer Immunotherapy Field

RESI @ TMCx Big Pharma Panel Announcement 



RESI Conference Group's Upcoming Events
LSN Videos
RESI 4 Recap Video, San Francisco, 2015
RESI 4 Investor Panel Videos
 Fundraising Boot Camp
Getting the Most from a 30-Minute Investor Meeting

By Michael Quigley, Director of Research, LSN 


As a fundraising entrepreneur, you will likely find yourself engaging in initial face-to-face meetings with investors, whether at a conference, coffee shop, or in an office. Given the time constraints inherent in these kinds of meetings, it is crucial that you have a plan in place in order to get as much as possible out of them. What follows are suggestions for how best to manage one of these conversations. 


In terms of what to bring for materials, a simple, cogent pitch deck made up of 10-12 slides can be a fantastic tool. However, before you even begin to present the first slides, you need to validate a fit between the investor and your company. This should be done in two steps.


With this information both of you will be able to determine whether further dialogue would be of value within the first few minutes of the meeting. Additionally, you will be able to determine what specifically the investor might find interesting about your opportunity, which you can then emphasize later in your conversation...

Global R&D Is Advancing the Cancer Immunotherapy Field
By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

The immuno-oncology field is seeing high-profile deals and increasing media attention.  We have therefore used the LSN company database to analyze a sample of biotech companies working in this field. Cancer immunotherapies harness the power of the immune system to target malignant cells. Unlike traditional approaches to cancer such as radiotherapy and chemotherapy, these emerging technologies hold the promise of precise therapeutic effects while leaving the rest of the body unharmed. These products' clinical benefits are impressive, and so is their financial performance. In 2014 alone, cancer immunotherapy drugs have generated about $41.0 billion in the United States, accounting for nearly 50% of the overall oncology drug market.


With more than 30,000 company profiles, LSN's company platform provides a bird's eye view of the global early stage biotech and medtech R&D landscape. Our search in the LSN company platform yielded 522 unique companies that are currently developing at least one cancer immunotherapy product. About one-fifth (119) of them are publicly listed, while the rest are private or subsidiary companies. Cancer immunotherapy R&D has become a global phenomenon with the United States the leader in terms of number of companies, followed by China, Germany, the United Kingdom, and Canada, as shown in Figure 1...




RESI @ TMCx Big Pharma Panel Announcement 

By Natasha Eldridge, Marketing Manager, Life Science Nation 


Panelists will discuss in-depth the key motivators behind big pharma's shift towards an early stage strategy as a way to fill the gaps in their pipelines. What indication areas are the most sought after? How does an early stage entrepreneur interface with business development executives from pharmaceutical companies? LSN's Big Pharma RESI Panelists will shed light on these questions and more.


Moderated by Donnie McGrath, VP, Business Development, Bristol-Myers Squibb this panel will feature:

  • Mark Ralph, Director, External Partnership Operations,Boehringer Ingelheim
  • Melinda Richter, Head, Johnson & Johnson Innovation, JLABS
  • Michael Martin, Senior Investment Director, Takeda Ventures, Inc.
  • Sylvaine Cases, Head of External Science & Partnering, US West, Sanofi

Hear from big pharma executives as they explain how they engage with early stage startups, and how they like to be contacted. The speakers will help the audience understand their timeline for contact, and give advice on how to create a dialogue that leads to a relationship and an eventual alliance. If you need to understand the timeframe and limitations of how big pharma corporate works, this expert session is crucial for you to attend.